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Streated at hospitals with an annual volume of less than 10
(9% of all resections) or an annual volume of less than 30
(45% of resections).
Given the relationship of volume to outcomes, and in the
interest of continued and continuous quality improvement,
hospitals should be aware of their annual volume for major
pulmonary resection and their institutional mortality
associated with those resections over time (at both 30
days and 90 days) compared with national data. Although
our methodology and analysis did not allow us to identify
an absolute break point or optimal minimum annual
volume, our data suggest the more the better and that
mortality continues to decline with increasing volume.
Benchmarking outcomes against those institutions perform-
ing more than 30 resections per year would attempt to
address much of the variation currently seen, and has
practical value. Those hospitals with low volume and/or
high mortality can then develop strategies to address the
differences in outcomes for their patients compared with
those treated at higher volume institutions with lower mor-
tality. Specific strategies to address low volume and/or high
mortality of major pulmonary resection are beyond the
scope of this report, but should be explored through future
efforts and investigation. To aid this process of continuous
quality improvement, the CoC now reports annual hospital
volume for major pulmonary resection, and 30-day mortal-
ity for those resections, to all CoC-approved programs
using NCDB data submitted by the hospitals on an annual
basis, as part of the Cancer Quality Improvement Program,
and starting in 2014 also plans to report 90-day mortality.References
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Dr Cameron D. Wright (Boston, Mass). Thank you, Dr Pezzi,
for a wonderful, very clear presentation. Using the National
Cancer Database to form a robust data set of 120,000 patients
who had a lung cancer resection, the authors have demonstrated
a modest, and I underline that word modest, volume/performance
relationship with an absolute mortality difference of 2% between
volumes less than 10 and greater than 90. The usual risk factors
for mortality were identified such as age. The authors picked a
somewhat arbitrary annual hospital volume of 30 without a
receiver operating characteristic curve analysis to define low
volume hospitals that they suggest should be carefully monitored
in terms of their results. Their volume/performance relationship
reporting is not new, and although this has been somewhat debated
in the literature, most reports do indeed suggest there is a modest
relationship, as this report does.
Of more interest to me is the substantial increase in mortality at
90 days, essentially doubling the 30-day mortality. This report
corroborates 2 very recent reports that also suggested doubling
of lung cancer mortality at 90 days, and in fact the mortality for
pneumonectomy at 90 days was a very sobering 14.6%. It begs
the question, are we misleading our patients when we counsel
them about their perioperative risk? We need to learn more about
what happens to our patients in this vulnerable period of time after
they are discharged to see if we can mitigate that risk. Obviously
this report cannot do that, but it certainly leads to an interesting
hypothesis and more work to be done. I have 2 questions.
First, why is there more volume/performance effect in the first
30 days versus the conditional 90 days? The odds ratio drops from
2 to a just slightly significant 1.3.
Dr Pezzi. Thank you, Dr Wright, for those comments and for
your first question, which is an excellent question. As far as the
reasons why we see a greater effect of volume on mortality during
the first 30 days than between 30 and 90 days, we honestly do
not know, but I wonder if this might suggest that some surgeon-
or institution-related factors are driving the 30-day mortality,diovascular Surgery c Volume 148, Number 5 2277
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Swhereas perhaps some patient-related or patient disease-related
factors, such as their tumors or comorbidities, are more respon-
sible for mortality between 30 and 90 days? We do still see an
effect on mortality between 30 and 90 days, but it is, as you
pointed out, significantly less. But this is just a hypothesis. I
certainly agree with you that we need to further study why these
patients are dying between 30 and 90 days, and hopefully that
will shed some light on what we can do to affect that mortality.
DrWright. And trending along that same line, where there is a
volume/performance relationship for pneumonectomy for the
30-day mortality, there is none for the conditional 90-day
mortality. Given the very large morbidity and mortality of
pneumonectomy, in which another 6% die in that 60-day window,
is this just a matter of small numbers? Why was that not
significant? What is your hypothesis there?
Dr Pezzi.Again, the overall magnitudewe saw across the board
seemed to decline between 30 and 90 days compared with the first
30 days, and perhaps we are dealing with small numbers, although
we did have 8000 pneumonectomies in this study, but perhaps it is
just small numbers. Again, I wonder if it could be patient-related
factors. I think as surgeons, we want to take responsibility for all
mortality of our patients, not just within 30 days, but even if a
patient dies 2 months later or 3 months later, I think we would
feel that somehow our operation might have contributed or had
something to do with that.
However, I think the longer we get out from the date of surgery,
it is possible that other factors beyond our control that are not
completely surgeon- or institution-related may be at play here,
and perhaps that is why we see a diminishing effect of volume
the further we get out from the date of surgery. This is just my
best guess to try to address your question.
Thank you very much for your comments and questions.
Dr Thomas K. Waddell (Toronto, Ontario). I enjoyed your
presentation. I want to follow up on Dr Wright’s question about
why the conditional mortality is not different in different size of
hospitals. Two questions to think about.
Are you able to describe any aspect of hospitals that have better
versus worse outcomes in that conditional mortality and are you
able to see postdischarge mortality as opposed to conditional
mortality based simply on the time points?
And the second question to think about, you presented
beautifully the evolution of 30-day mortality over time. Do you
have any data about the evolution of conditional mortality over
time? Is this also getting better or has it always been the same
magnitude of problem?
Dr Pezzi. To address your last question first, I think it is an
excellent question, and that is, we have traditionally defined
surgical mortality as 30 days or during the initial admission, and
so we do not have too much data on 90-day mortality over the
decades. And so I guess the question that comes to mind is: has
this mortality been there all along and we just did not notice it,
or is there something different now that we are essentially pushing
some of the mortality that used to occur in the first 30 days beyond
30 days? In talking to our surgical intensivists, they can keep sick2278 The Journal of Thoracic and Cardiovascular Surpatients alive longer, perhaps beyond 30 days, but maybe not
beyond 90 days. And so are we just pushing on some of that
mortality?
You talked about discharges. These are actually 30 and 90 days
and have nothing to do with hospitalization. We really did not look
at time of discharge or various hospitalizations. We are just
looking at crude survival at 30 and 90 days.
I think this is important, because at my own institution, if a
patient is doing poorly and they are not going to make it, and it
looks bad, and they have been on a ventilator for 4 weeks, a lot
of times they get sent to hospice and they are considered
discharged at that point and they are readmitted to hospice. And
so they would not be picked up as either a 30-day mortality or
an initial hospitalization mortality. They are considered
discharged. So I think that is an excellent point you bring up.
I hope I answered your question.
Dr Tomasz Grodzki (Szczecin, Poland). I have 1 short
question. Why did you decide that 90 cases per year is high
volume? European standards consider more than 200 as high
volume. It means that it is 2 cases per week. If you have 3 surgeons,
every single surgeon is doing less than 1 case per week. It is not a
high volume.
Dr Pezzi. Thank you. That is an excellent question. It was, as
Dr Wright pointed out and I would acknowledge, a weakness,
that it was somewhat arbitrary how we divided our volume groups.
I would point out that only 21 hospitals were in that high volume
group out of 1200. So to set the bar even higher would have led to
an even smaller number of hospitals.
Dr Mark J. Krasna (Neptune, NJ). Congratulations, Chris, to
you and the authors from the Commission on Cancer. I believe 1 of
the points also to take away from here, if I am not mistaken, is that
the Commission on Cancer data are currently reported back to the
hospitals, and it is not specified whether the surgeons performing
the operations were thoracic surgeons versus nonthoracic
surgeons. I do think it would be very interesting going forward
in a prospective fashion if you could get granular data to identify
not only the high volume from the low volume hospitals but also
identify hospitals where most of the surgery was done by thoracic
surgeons versus general surgeons.
I know in the past we have heard many papers about this, but
I do think using the NCDB data, we could maybe put in that
granularity and ask for that information going forward. I think it
is a very good start.
Dr Pezzi. Thank you very much. Yes, the NCDB currently is a
hospital-based registry, but they will be using National Provider
Identifier (NPI) numbers to report surgeon-specific data going
forward. It was not available in this data set, but in the future
that will be available using NPI numbers.
Dr Scott Swanson (Boston, Mass). Nice paper. One quick
question. You may have said it and I missed it. Why is 90 days
the max? Do we know what happens at 4 months, 6 months,
1 year? Does it flatten out and do you know that?
Dr Pezzi. That is an excellent question. We did not look at that
but I think we should.gery c November 2014
